Company intelligence / Profile preview

DanCann Pharma

Ownership: Private
Employees: ~5
Development stage: Other

Overview

DanCann Pharma is developing a pipeline of cannabinoid-based therapeutics focused on pain, including EXT02 CannGros, EXT03 CannGros, EXT04 CannGros, FLS04 CannGros, and FLS05 CannGros, primarily in pre-clinical stages. It also imports and distributes products like Bedrocan CannGros, Bedica CannGros, and Bediol CannGros.[1][3]

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

3 assets

EXT03

2 more assets in the full pipeline.

Beyond the preview

Go deeper on DanCann Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DanCann Pharma.